Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...

A 40-year-old woman announced her death on Facebook this past December. Rachel Davies from the UK was diagnosed with ...

Developed by the NanoBRIGHT project consortium, the new platform employs vibrational fiber photometry as a method to "image the cytoarchitecture of the mouse brain, monitor molecular alterations ...

Orion's collaboration partner Bayer submits application in China for third indication of darolutamide ...

An innovative technique, termed the 'molecular lantern', enables non-invasive monitoring of molecular changes in the brain, ...

A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...

Astellas Pharma’s Vyloy receives China NMPA approval for first-line treatment of advanced gastric or GEJ adenocarcinoma: Tokyo Tuesday, January 7, 2025, 09:00 Hrs [IST] Astellas ...

The following is a summary of “Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and ...

Heart disease and cancer might seem completely unrelated, but these two top causes of death sometimes act in concert. Women ...

Preoperative stereotactic radiosurgery to treat brain metastases resulted in low rates of local recurrence, radionecrosis, ...

SHRA-1921 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Metastatic Breast Cancer.

Astellas Pharma Inc. (ALPMY, ALPMY) announced that China's National Medical Products Administration approved VYLOY (zolbetuximab), in ...